Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 06 - 28 save search
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
SLE-UPDATE Study Finds Reducing Pain, Fatigue, and Flares are Top Treatment Goals for People with Lupus
Published: 2021-06-28 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -0.34%
treatment lupus
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 13:15) - crinetics.com
CRNX | $42.98 -0.07% -0.07% 620K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 4.25%
H: 2.09%
C: -5.49%
treatment fda fda fast track fast track leukemia fast track designation granted grant designation
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
CRNX | $42.98 -0.07% -0.07% 620K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: 1.32%
H: 0.35%
C: -2.4%
treatment europe application
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
RMTI | $1.46 -1.35% -1.37% 82K
|
Health Technology
|
| O: 3.06%
H: 4.26%
C: 2.14%
treatment fda iron deficiency anemia trial
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.81%
H: 3.23%
C: -3.23%
covid treatment potential
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Published: 2021-06-28 (Crawled : 06:00) - globenewswire.com
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.23%
H: 1.84%
C: -1.61%
treatment phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
LEV | $0.972 0.73% 2.88% 570K
|
Manufacturing
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.